NCT02059174View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)

PHASE1CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

February 10, 2014

Primary Completion Date

March 30, 2015

Study Completion Date

April 27, 2015

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

MK-1293

MK-1293 0.4 units/kg administered subcutaneously

DRUG

EU-Lantus™

EU-Lantus™ 0.4 units/kg administered subcutaneously

DRUG

Novolog™

Participants will receive an intravenous infusion of insulin aspart (Novolog™ or other rapid-acting insulin analog) for several hours prior to MK-1293 or EU-Lantus™ dosing in each dosing period to meet basal insulin requirements

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02059174 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005) | Biotech Hunter | Biotech Hunter